| Bioactivity | Leucettinib-21 (LCTB-21) (compound 4) is a potent, selective DYRK1A inhibitor with IC50 of 2.4, 6.7, 12, 33, and 5 nM for DYRK1A, DYRK1B, CLK1, CLK2, and CLK4, respectively. Leucettinib-21 can be used for Down syndrome and Alzheimer's disease study[1]. |
| Name | Leucettinib-21 |
| CAS | 2732859-75-3 |
| Formula | C18H22N4O2S |
| Molar Mass | 358.46 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Lindberg MF, et al. Chemical, Biochemical, Cellular, and Physiological Characterization of Leucettinib-21, a Down Syndrome and Alzheimer's Disease Drug Candidate. J Med Chem. 2023;66(23):15648-15670. |
Leucettinib-21
CAS: 2732859-75-3 F: C18H22N4O2S W: 358.46
Leucettinib-21 (LCTB-21) (compound 4) is a potent, selective DYRK1A inhibitor with IC50 of 2.4, 6.7, 12, 33, and 5 nM fo
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.